Certain rare genetic variants tied to Parkinson’s and other diseases raise the risk of developing ALS by more than three times, per a study.

Ractigen's therapy candidate RAG-17 was safe across all tested doses and showed early signs of effectiveness in SOD1-ALS ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

Fourteen years into an ALS diagnosis, columnist Dagmar Munn decides in a visit to the dermatologist that she's earned her little skin bumps.

NRG Therapeutics will use a new grant to advance preclinical studies of its class of oral small molecules as a potential ...

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the ...

The FDA has granted orphan drug status to Actimed Therapeutics' S-oxprenolol, a treatment candidate that aims to ease muscle ...

Measuring the levels of a novel protein biomarker called CXCL12 in the spinal fluid may improve the diagnosis of ALS, per a ...

A strategy that simultaneously targets motor neurons, astrocytes, and microglia in ALS was found to extend survival in a ...

Living with her late husband's ALS taught columnist Juliet Taylor valuable lessons about what strength and weakness really ...

Columnist Dagmar Munn, who worked in the fitness profession, knows that movement matters — so she plans a recess break for every hour.

Columnist Kristin Neva reflects on her last state park outing with her husband, which seems a lifetime ago to her now.